India
· Delayed Price · Currency is INR GlaxoSmithKline Pharmaceuticals Statistics
Total Valuation
GlaxoSmithKline Pharmaceuticals has a market cap or net worth of INR 477.37 billion. The enterprise value is 458.99 billion.
| Market Cap | 477.37B |
| Enterprise Value | 458.99B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | May 31, 2024 |
Share Statistics
GlaxoSmithKline Pharmaceuticals has 169.41 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Shares Outstanding | 169.41M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 8.18% |
| Float | 41.37M |
Valuation Ratios
The trailing PE ratio is 74.60 and the forward PE ratio is 54.13.
| PE Ratio | 74.60 |
| Forward PE | 54.13 |
| PS Ratio | 13.62 |
| PB Ratio | 26.85 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 71.71 |
| EV / Sales | 13.09 |
| EV / EBITDA | 46.59 |
| EV / EBIT | 49.59 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 1.05 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | n/a |
| Interest Coverage | 490.08 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 32.56% |
| Revenue Per Employee | 10.92M |
| Profits Per Employee | 1.99M |
| Employee Count | 3,211 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +92.97% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +92.97% |
| 50-Day Moving Average | 2,745.83 |
| 200-Day Moving Average | 2,275.04 |
| Relative Strength Index (RSI) | 50.27 |
| Average Volume (20 Days) | 5,618 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GlaxoSmithKline Pharmaceuticals had revenue of INR 35.07 billion and earned 6.40 billion in profits. Earnings per share was 37.77.
| Revenue | 35.07B |
| Gross Profit | 21.52B |
| Operating Income | 9.26B |
| Pretax Income | 8.85B |
| Net Income | 6.40B |
| EBITDA | 9.68B |
| EBIT | 9.26B |
| Earnings Per Share (EPS) | 37.77 |
Balance Sheet
The company has 18.57 billion in cash and 186.65 million in debt, giving a net cash position of 18.38 billion or 108.51 per share.
| Cash & Cash Equivalents | 18.57B |
| Total Debt | 186.65M |
| Net Cash | 18.38B |
| Net Cash Per Share | 108.51 |
| Equity (Book Value) | 17.78B |
| Book Value Per Share | 104.93 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 61.38%, with operating and profit margins of 26.40% and 18.25%.
| Gross Margin | 61.38% |
| Operating Margin | 26.40% |
| Pretax Margin | 25.23% |
| Profit Margin | 18.25% |
| EBITDA Margin | 27.59% |
| EBIT Margin | 26.40% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 32.00, which amounts to a dividend yield of 1.14%.
| Dividend Per Share | 32.00 |
| Dividend Yield | 1.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | 1.10% |
| Earnings Yield | 1.34% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on September 11, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Sep 11, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |